Ultragenyx Pharmaceutical Inc. (RARE) Sells PRV for $203M

Ultragenyx sold a priority review voucher for rare pediatric diseases to an undisclosed buyer for $203 million. The voucher, granted by the FDA, can expedite the review of a future drug application. Ultragenyx's stock has declined 35.13% year-to-date.

Ultragenyx Pharmaceutical (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203 million in cash. The voucher, awarded by the FDA in September 2026, is tied to the approval of FAYUVI (UX111) for MPS IIIA. The transaction, subject to closing conditions, aims to monetize the voucher and support strategic priorities.

Ultragenyx Pharmaceutical (RARE) sold a Rare Pediatric Disease Priority Review Voucher for $203M. The voucher was received after FDA approval of FAYUVI, a treatment for Sanfilippo syndrome Type A. This is Ultragenyx's second such sale in a week. The deal is subject to regulatory approval. Jefferies LLC and Gibson Dunn are advisors.

Ultragenyx Pharmaceutical Inc. (RARE) announced a $203 million deal to sell a Rare Pediatric Disease Priority Review Voucher (PRV). This is the company's second PRV sale in a week, with proceeds aimed at funding innovative treatments and supporting profitability. The transaction is subject to customary closing conditions, including antitrust review. Jefferies LLC and Gibson, Dunn and Crutcher LLP are advising Ultragenyx on the deal.

Ultragenyx sold a rare pediatric priority review voucher (PRV) for $210m, awarded after FDA approval of GENGLYCOS, a gene therapy for glycogen storage disease type Ia. The company plans to use the proceeds to advance rare disease therapies and support profitability, according to its CFO. The transaction is subject to customary closing conditions.

Ultragenyx sold its Rare Pediatric Disease Priority Review Voucher for $210M, earned for Genglycos. Viatris agreed to acquire Pacira BioSciences for $1.65B, adding non-opioid pain therapies. Peter Young notes improving financing and M&A activity in biopharma despite policy and patent challenges.